南旧金山 - 专注于严重病毒性疾病的生物技术公司Assembly Biosciences, Inc. (NASDAQ:ASMB)公布了其慢性乙型肝炎病毒 (HBV)感染治疗药物候选ABI-4334的1b期研究中期结果。研究显示了良好的安全性和药代动力学特征，以及患者中显著的抗病毒活性。根据 InvestingPro 数据，该公司目前市值9356万美元，年初至今的市场表现强劲，回报率为49.58%。

OraSure Technologies, Inc. OSUR recently announced the acquisition of Sherlock Biosciences, Inc., a global health company ...

Shares of Assembly Biosciences advanced after the company reported encouraging results from a clinical trial of its treatment for the hepatitis B virus. The stock was up 5.2% at $15.49 in premarket ...

Pulse Biosciences' Nano-Pulse Stimulation technology has indications in several complex medical disorders. Read why I ...

在其他近期新闻中，Assembly Biosciences与吉利德科学公司的合作取得了重大进展。两家公司修订了协议，Assembly Biosciences从吉利德科学公司获得了1000万美元的即时付款，用于他们共同的药物开发项目ABI-6250。此外，吉利德科学公司增持了Assembly Biosciences的股份，购买了940,499股普通股。

经典先天性肾上腺增生症是指一组遗传性代谢疾病，患者缺乏促进肾上腺激素生产的酶。大约95%的CAH病例是由导致21-羟化酶缺乏的突变引起的。在经典CAH中，这种酶的严重缺乏会导致肾上腺不能产生皮质醇，在大约75%的病例中，会导致醛固酮缺乏。如果不及时治疗，经典CAH可导致患者盐耗、脱水，甚至死亡。糖皮质激素是该疾病的标准疗法。

A Relative Strength Rating upgrade for Neurocrine Biosciences shows improving technical performance. Will it continue?

Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of ...

Neurocrine’s Crenessity approval for CAH treatment represents a transformative opportunity. See why I maintain my strong buy ...

世界农化网中文网 报道： 跨国公司美国美盛（Mosaic）近日在巴西市场推出了一款新生物营养解决方案 MBio Stimulus，专为叶面施用而设计。MBio Stimulus 含有营养成分和氨基酸，现在加入了 Mosaic Biosciences Brasil 的产品组合中。此前该产品组合种有 4 款产品，于今年 3 月推出。 美盛表示，MBio Stimulus ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced its participation in the 43rd Annual J.P. Morgan ...

Solid Biosciences ended Q3 2024 with $171.1 million in cash, securing operations through 2026. Initial Phase 1/2 trial ...